(firstQuint)Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis.

 is a multicenter, randomized, double-blind, placebo-controlled phase II study.

 The trial includes a Run-in Period (if stable conventional treatment needed), a 4-week Screening Period, a 12-week Treatment Period, and a 3-week Safety Follow-up Period to Day 105.

 90 patients will be centrally, dynamically, randomly assigned to 3 groups (1:1:1) to receive 600mg TJ301 biweekly (Q2W), 300mg TJ301 Q2W or placebo Q2W.

.

 Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis@highlight

This is a multicenter, randomized, double-blind, placebo-controlled phase II study.

